Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (10822)	2/12/1999 8:25:00 AM
From: Doorman	Respond to of 122088

Thanks Henry. Excellent info and wonderful website. Good work! Appreciated definition of "Proof of Principle": "Bristol does, however, retain the option to reassume development and marketing rights for angiostatin once "clinical proof of principal" has been demonstrated, the statement said. In its filing Thursday, EntreMed defined "proof of principle" as the completion of Phase II human clinical trials showing safety and efficacy of the protein." Completion of Ph 2 is a long ways off if it happens at all. Also according to the 8K filing: "Currently, Bristol has agreed to provide EntreMed with "advice" on structuring its clinical program but otherwise will have no direct involvement with the development of angiostatin, according to the filing." This seems to contradict ENMD Chairman and Chief Executive John Holaday who said in a 2/10 Dow Jones story:"(Bristol-Myers) will continue to work with the molecule, and the clinical trial people will be working with us as we head into the Phase I studies at the end of the year." Henry's site also has today's NY Times and WSJ newest articles which I'll post. Thanks again.